URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Barbara L. Asselin

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentPediatrics
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 777
Rochester NY 14642
Other Positions
TitleProfessor
InstitutionUniversity of Rochester Medical Center
DepartmentCancer Center

 
 Awards And Honors
1977     Honor Society of Phi Beta Kappa
1977     Honor Society of the Order of the Cross and Crown
1980     Rochester Academy of Medicine OB-GYN Annual Award
1980     Paul Gyorgy Annual Award, La Leche League International
1985 - 1986Bradford Fellow  | Department of Pediatrics
1987 - 1990Research Fellow, Leukemia Society of America
1987 - 1990Wilmot Cancer Research Fellow  | James P. Wilmot Foundation
1998     Society of Pediatric Research
2002 - 2005George Washington Goler Associate Professor of Pediatrics
2002     Jacob Gitelman Award  | Cancer Action and Gilda's Club of Rochester
2003 - 2010Alpha Omega Alpha (AOA) Medical Honor Society
2004 - 2014Best Doctors in America
 
 Overview
My primary interest is in clinical trials and clinical research in treatment of pediatric malignancies. I serve as the Principal Investigator for the Clinical Research Program in Pediatric Oncology for all cooperative group activities through the Children's Oncology Group and the Dana-Farber Leukemia Consortium. Through these groups, I have been actively involved in design and development of a number of studies of the treatment and biology of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). My specific areas of expertise are L-asparaginase pharmacology, pharmacodynamics and immunology in treatment of ALL, treatment of T-cell disease (ALL and NHL), and role of cardioprotectants in preventing cardiotoxicity of cancer therapy.

 
 Selected Publications
List All   |   Timeline
  1. Asselin BL, Gaynon P, Whitlock JA. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol. 2013 Dec; 25 Suppl 3:S1-S13.
    View in: PubMed
  2. Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 1; 119(19):3555-62.
    View in: PubMed
  3. Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013 Jul 25; 122(4):507-14.
    View in: PubMed
  4. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10.
    View in: PubMed
  5. Liesveld J, Asselin B. It's ALL in the Liposomes: Vincristine Gets a New Package. J Clin Oncol. 2013 Feb 20; 31(6):657-9.
    View in: PubMed
  6. Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11.
    View in: PubMed
  7. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 1; 30(10):1042-9.
    View in: PubMed
  8. Asselin BL. The right dose for the right patient. Blood. 2012 Feb 16; 119(7):1617-8.
    View in: PubMed
  9. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011 Dec; 33(8):610-6.
    View in: PubMed
  10. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9.
    View in: PubMed
  11. Asselin BL. L-asparaginase for treatment of childhood acute lymphoblastic leukemia: what have we learned? Pediatr Blood Cancer. 2011 Sep; 57(3):357-8.
    View in: PubMed
  12. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011 Jul 28; 118(4):874-83.
    View in: PubMed
  13. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct; 11(10):950-61.
    View in: PubMed
  14. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205.
    View in: PubMed
  15. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb; 24(2):320-34.
    View in: PubMed
  16. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3.
    View in: PubMed
  17. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 1; 26(7):1106-11.
    View in: PubMed
  18. Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res. 2007 Jul-Aug; 27(4C):2561-72.
    View in: PubMed
  19. Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2007 Jun; 29(6):369-75.
    View in: PubMed
  20. Winter SS, Jiang Z, Khawaja HM, Griffin T, Devidas M, Asselin BL, Larson RS. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2007 Sep 1; 110(5):1429-38.
    View in: PubMed
  21. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 1; 25(7):813-9.
    View in: PubMed
  22. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 1; 109(3):896-904.
    View in: PubMed
  23. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005 Nov 1; 23(31):7958-66.
    View in: PubMed
  24. Savasan S, Buck S, Ozdemir O, Hamre M, Asselin B, Pullen J, Ravindranath Y. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2005 Jun; 46(6):833-40.
    View in: PubMed
  25. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 8; 351(2):145-53.
    View in: PubMed
  26. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 1; 21(19):3616-22.
    View in: PubMed
  27. Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 1; 21(15):2953-60.
    View in: PubMed
  28. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002 Mar 15; 20(6):1677-82.
    View in: PubMed
  29. LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, Lipshultz SE, Declerck L, Silverman LB, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 1; 20(1):237-46.
    View in: PubMed
  30. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 1; 97(5):1211-8.
    View in: PubMed
  31. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56.
    View in: PubMed
  32. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):6-12.
    View in: PubMed
  33. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999; 457:621-9.
    View in: PubMed
  34. Graham ML, Asselin BL, Herndon JE, Casey JR, Chaffee S, Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, Kurtzberg J. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 1998 May; 21(9):879-85.
    View in: PubMed
  35. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998 Jan; 27(1):53-68.
    View in: PubMed
  36. Snitzer EL, Fultz PJ, Asselin B. Magnetic resonance imaging appearance of fibromatosis colli. Magn Reson Imaging. 1997; 15(7):869-71.
    View in: PubMed
  37. Korones DN, Buzzard CJ, Asselin BL, Harris JP. Right atrial thrombi in children with cancer and indwelling catheters. J Pediatr. 1996 Jun; 128(6):841-6.
    View in: PubMed
  38. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993 Sep; 11(9):1780-6.
    View in: PubMed
  39. Asselin BL. Evaluation of tumor cell heterogeneity based on response to chemotherapy. Clin Chim Acta. 1992 Mar 13; 206(1-2):33-44.
    View in: PubMed
  40. Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakley RL, Cohen HJ. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991 Dec 15; 51(24):6568-73.
    View in: PubMed
  41. Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE, Cohen HJ. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989 Aug 1; 49(15):4363-8.
    View in: PubMed
  42. Asselin BL, Lawrence RA. Maternal disease as a consideration in lactation management. Clin Perinatol. 1987 Mar; 14(1):71-87.
    View in: PubMed
  43. Pouillart P, Palangie T, Garcia-Giralt E, Jouve M, Bataini JP, Jaulerry M, Brugère J, Asselin B. [Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. Bull Cancer. 1980; 67(3):269-80.
    View in: PubMed

Visualizations


Asselin's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department